Gesynta Pharma develops novel anti-inflammatory, pain-relieving pharmaceuticals

READ MORE

Vipoglanstat (GS-248) to enter clinical phase II development targeting endometriosis

Read more

Our pipeline

Gesynta Pharma’s drug candidates utilize a unique mechanism of action to reduce inflammation and pain. We are currently developing two drug candidates. Vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I. Read more about our drug development projects.

Therapeutic areas

Endometriosis affects the lives of millions of women

READ MORE

Development pipeline

Vipoglanstat - our most advanced drug candidate

READ MORE

News & Media

Read about our recent progress

READ MORE

Development pipeline

Unique treatments of chronic inflammation

READ MORE

Development pipeline

Leading the development of novel pharmaceuticals that target pain and inflammation

Gesynta Pharma develops pharmaceutical treatments addressing inflammation – a key underlying driver in a spectrum of diseases. The most advanced drug candidate vipoglanstat is currently in development for the treatment of endometriosis – a painful chronic inflammatory disease that affects about 10 percent of women of reproductive age. Vipoglanstat is a non-hormonal, potentially disease-modifying drug candidate that inhibits the proinflammatory enzyme mPGES-1. In phase I and II clinical trials, the drug candidate has demonstrated a favorable safety profile and beneficial pharmacological properties. A preclinical proof-of-concept study in an advanced disease model of endometriosis shows that vipoglanstat significantly reduces endometrial lesions and has a positive impact on pain-related parameters and well-being. Based on these robust data, Gesynta Pharma aims to shortly initiate a phase II clinical trial of vipoglanstat in patients with endometriosis.

Gesynta Pharma’s second drug candidate to reach clinical development, GS-073, has the same mode of action as vipoglanstat. GS-073 is ready to enter clinical phase I for the treatment of chronic inflammatory pain.

READ MORE

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.